95798-23-5

Basic information

• Product Name: Benzyl 4-hydroxy-1-piperidinecarboxylate
• Synonyms: N-CBZ-4-HYDROXY-1-PIPERIDINE;BENZYL 4-HYDROXY-1-PIPERIDINECARBOXYLATE;BENZYL 4-HYDROXYPIPERIDINE-1-CARBOXYLATE;BENZYL 4-HYDROXYTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;BUTTPARK 93\50-53;4-HYDROXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;4-HYDROXYPIPERIDINE, N-CBZ PROTECTED;4-Hydroxypiperidine, N-CBZ protected 97%
• CAS NO: 95798-23-5
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Product Categories: pharmacetical;API intermediates;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 95798-23-5.mol
• Article Data: 47

Chemical Properties

• Boiling Point: 167 °C0.2 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.554 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.3E-06mmHg at 25°C
• Refractive Index: n20/D 1.543(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 14.79±0.20(Predicted)
• CAS DataBase Reference: Benzyl 4-hydroxy-1-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 4-hydroxy-1-piperidinecarboxylate(95798-23-5)
• EPA Substance Registry System: Benzyl 4-hydroxy-1-piperidinecarboxylate(95798-23-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37/39
• WGK Germany: 3
• Hazardous Substances Data: 95798-23-5(Hazardous Substances Data)

Usage

Uses

Reactant for synthesis of: Orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation Piperidine derivatives Molecular rods Oxazolidinone-quinolone hybrids and their antibacterial activity Cyclic prodrug of RGD peptidomimeticReactant for oxidation of alcohols

InChI:InChI=1/C13H17NO3/c15-12-6-8-14(9-7-12)13(16)17-10-11-4-2-1-3-5-11/h1-5,12,15H,6-10H2

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 619-45-4 4-methoxycarbonyl aniline 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 110-89-4 piperidine 
• 97231-85-1 4-(tert-butyldimethylsilyloxy)piperidine-1-carboxylic acid benzyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 3742-91-4 N-(benzyloxycarbonyl)piperidine 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 620-73-5 phenyl chloroacetate 
• 5382-17-2 piperidin-4-ol hydrochloride 

Downstream Products

• 144412-43-1 t-Butyl 2-(1-benzyloxycarbonyl-4-piperidyl)oxyacetate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 733810-73-6 phenylmethyl 4-phenylhexahydropyridine-1-carboxylate 
• 933477-82-8 [(1-benzyloxycarbonylpiperidin-4-yl)oxy]acetic acid methyl ester 
• 1612172-50-5 4-(trifluoromethoxy)piperidine hydrochloride 
• 144412-48-6 {1-[(S)-2-(4-Carbamimidoyl-benzoylamino)-propionyl]-piperidin-4-yloxy}-acetic acid tert-butyl ester 
• 146117-96-6 [1-((R)-2-Benzyloxycarbonylamino-propionyl)-piperidin-4-yloxy]-acetic acid tert-butyl ester 
• 215453-70-6 [1-((S)-2-Benzyloxycarbonylamino-propionyl)-piperidin-4-yloxy]-acetic acid tert-butyl ester 
• 144412-18-0 Ro 44-3888 
• 146118-12-9 t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate 

Relevant articles and documents

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

The ever-growing prevalence of Type-2 diabetes in the world has an urgent need for multiple orally effective agents that can regulate glucose homeostasis. G-Protein coupled receptor 119 (GPR 119) agonists have demonstrated the glucose-dependent insulin secretion and showed beneficial effects on glycemic control in humans and/or relevant animal models. Herein, we describe our efforts towards identification of a potent and oral GPR 119 agonist 13c (ZY-G19), which showed in vitro potency in the cell-based assay and in vivo efficacy without exerting any significant signs of toxicity in relevant animal models.

CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

Chemoselective Oxidation of p-Methoxybenzyl Ethers by an Electronically Tuned Nitroxyl Radical Catalyst

The oxidation of p-methoxy benzyl (PMB) ethers was achieved using nitroxyl radical catalyst 1, which contains electron-withdrawing ester groups adjacent to the nitroxyl group. The oxidative deprotection of the PMB moieties on the hydroxy groups was observed upon treatment of 1 with 1 equiv of the co-oxidant phenyl iodonium bis(trifluoroacetate) (PIFA). The corresponding carbonyl compounds were obtained by treating the PMB-protected alcohols with 1 and an excess of PIFA.